Rheumatic disorder
MONDO:0005554Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.
Also known as: rheumatic disease, rheumatologic disorder, collagen disease, collagen vascular disease, connective tissue disease, disease, rheumatic, diseases, rheumatic, enthesopathies
1584 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 630 trials in this tab.
-
Can the MenB vaccine protect kids with rheumatic conditions?
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing the meningococcal B vaccine (Bexsero) in children and young adults aged 2 to 25 who have autoimmune rheumatic diseases like juvenile arthritis or lupus. Researchers want to see if the vaccine triggers a strong immune response and if it is safe, especially fo…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:10 UTC
-
Could a dengue vaccine be safe for autoimmune patients? new trial aims to find out
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
New vaccine trial aims to shield vulnerable children from pneumonia
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the safety and immune response of the 20-valent pneumococcal vaccine (PCV20) in children, adolescents, and young adults aged 2-25 with autoimmune rheumatic diseases like juvenile arthritis. All 114 participants will receive one dose of PCV20, and researchers will…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:11 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThis study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
Disease control Recruiting nowThis Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to tame heart sarcoidosis with fewer side effects
Disease control Recruiting nowThis Phase 3 trial compares a low-dose combination of prednisone and methotrexate to standard high-dose prednisone for people with active cardiac sarcoidosis. Researchers hope the combo works just as well but causes fewer side effects and improves quality of life. The study plans…
Phase: PHASE3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Second-Time ACL repair: new technique shows promise for knee stability
Disease control Recruiting nowThis study looks at how well a particular revision ACL surgery works over the long term. The technique uses a donor Achilles tendon and an extra stitch on the outside of the knee. Researchers will check knee function, stability, and arthritis development in 59 people who had this…
Sponsor: Stefano Zaffagnini • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New lupus drug E6742 enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether the experimental drug E6742 can reduce lupus disease activity better than a placebo. About 256 adults with lupus will take either E6742 or a placebo pill for 24 weeks. The main goal is to see if more people on E6742 achieve a meaningful reduction …
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New study tests ilaris to tame rare inflammatory disease
Disease control Recruiting nowThis study looks at how well and how safely the drug Ilaris (canakinumab) works for people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. About 5 participants will receive the drug and be monitored for up to 48 weeks. The goal is t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New shoulder implant under real-world scrutiny: will it hold up?
Disease control Recruiting nowThis study follows adults who have received a Tipmed shoulder replacement to see how well the implant works and if any problems arise over the first year. Participants have conditions like severe arthritis, rotator cuff damage, or a broken shoulder bone. Researchers track shoulde…
Sponsor: TIPMED Medical Device Manufacturing Ltd. Co. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Lupus trial tests NAD+ booster to tame immune system
Disease control Recruiting nowThis study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug ABBV-519 enters first human tests for lupus and arthritis
Disease control Recruiting nowThis early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Blood test could help rheumatoid arthritis patients safely reduce medication
Disease control Recruiting nowThis study tests a new tool called OPTIBIO that uses blood markers and patient data to help doctors decide if it's safe to reduce biological therapy in rheumatoid arthritis patients who are in remission. About 184 adults with RA in stable remission will be randomly assigned to ha…
Phase: NA • Sponsor: Francisco J. Blanco • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with joint pain: risankizumab trial launches
Disease control Recruiting nowThis study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New mRNA injection aims to tame autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Lupus drug trial aims for remission without daily pills
Disease control Recruiting nowThis study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New RA drug enters first human safety trial
Disease control Recruiting nowThis study tests a new medicine called SBT777101 in 24 people with moderate-to-severe rheumatoid arthritis (RA). It is the first time this drug is given to humans, so the main goal is to check safety and side effects. Participants receive a single dose, and the dose is increased …
Phase: PHASE1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New lupus drug aims to help patients stop steroids
Disease control Recruiting nowThis study tests a medicine called anifrolumab for people with lupus who have not taken strong immune-suppressing drugs before. The goal is to see if the drug can help patients reach remission and reduce or stop their steroid use. About 245 adults will receive weekly injections f…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to tame lupus flares
Disease control Recruiting nowThis study tests an experimental drug called IMC-002 (also known as IMM0306) in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial compares the drug against a placebo, both given alongside standard care, to see if it can reduce disease …
Phase: PHASE1, PHASE2 • Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for tough arthritis cases: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called Afimkibart (RO7790121) in 160 people with moderate to severe rheumatoid arthritis who did not get better with or could not tolerate standard treatments like TNF or JAK inhibitors. Participants will receive either the drug or a placebo …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Morning or evening? timing your RA pill could boost relief
Disease control Recruiting nowThis study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare …
Sponsor: Centre Hospitalier Princesse Grace • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called CHT101 for people with severe lupus that hasn't improved with standard treatments. CHT101 uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that drive lupus. The study will enroll 15…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis without biologics
Disease control Recruiting nowThis Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug tulisokibart aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug afimkibart tested for Long-Term arthritis control
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for kids with arthritis: experimental drug enters final testing phase
Disease control Recruiting nowThis study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive eithe…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests an experimental drug called dapirolizumab pegol for people with moderate to severe lupus. About 450 participants will receive either the drug or a placebo, added to their usual treatments. The goal is to see if the drug can improve lupus symptoms over 48 weeks.
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells aim to tame lupus without daily pills
Disease control Recruiting nowThis phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New lupus pill enters Mid-Stage trial – hope for better control?
Disease control Recruiting nowThis study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tame painful muscle condition and cut steroid dependence
Disease control Recruiting nowThis study tests whether adding sarilumab (a drug that calms inflammation) to a slow steroid taper can help people with early polymyalgia rheumatica achieve lasting remission. About 300 adults aged 50 and older will receive either sarilumab or a placebo, along with a 52-week pred…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug AZD5492 tested for autoimmune diseases in first human study
Disease control Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug AZD1163 aims to ease rheumatoid arthritis pain
Disease control Recruiting nowThis study tests an experimental drug called AZD1163 in 320 people with moderate-to-severe rheumatoid arthritis who haven't gotten enough relief from standard treatments. Participants receive either AZD1163 or a placebo as an injection, along with their usual care. The main goal …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lupus drug may shield heart and arteries
Disease control Recruiting nowThis study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill could ease arthritis in kids – major trial underway
Disease control Recruiting nowThis study tests whether baricitinib, a daily pill, is safe and works for children aged 1 to under 18 with systemic juvenile idiopathic arthritis (sJIA), a chronic inflammatory disease. About 58 children will receive either baricitinib or a standard injected drug (tocilizumab) to…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New RA drug enters early safety testing
Disease control Recruiting nowThis early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug. The study lasts…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with arthritis: baricitinib Long-Term trial underway
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a single infusion of modified immune cells tame lupus kidney flares?
Disease control Recruiting nowThis study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …
Phase: PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug takes aim at autoimmune diseases in early human test
Disease control Recruiting nowThis early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lupus drug aims to cut steroid use in italian patients
Disease control Recruiting nowThis study follows 218 adults with systemic lupus erythematosus (SLE) in Italy who are starting anifrolumab (Saphnelo) for the first time. Researchers want to see if the drug helps patients reach a state of low disease activity while taking 5 mg or less of steroids daily. The stu…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug trial aims to tame overactive immune system in lupus patients
Disease control Recruiting nowThis early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double whammy for AFib: single procedure aims to fix rhythm and prevent strokes
Disease control Recruiting nowThis study tests doing two heart procedures at the same time for people with atrial fibrillation. First, doctors use pulsed field energy to fix the heart's rhythm. Then, they implant a small device to close off a part of the heart where clots can form. The goal is to see if this …
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for arthritis sufferers: experimental drugs enter human trials
Disease control Recruiting nowThis phase 2 study tests two experimental drugs, lutikizumab and ravagalimab, alone or together, in about 180 adults with moderate-to-severe rheumatoid arthritis who have not improved with other treatments. The goal is to see if these drugs can reduce joint pain and swelling bett…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lupus drug anifrolumab put to the test in everyday clinics
Disease control Recruiting nowThis study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict rese…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug MK-1045 enters early human testing for lupus and RA
Disease control Recruiting nowThis early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Still's disease: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called MAS825 for people with Still's disease, a rare inflammatory condition causing fever, rash, and joint pain. About 20 children and adults with active disease will receive the drug to see if it safely controls symptoms. The goal is to improve d…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can an IV drip replace the needle for arthritis patients?
Disease control Recruiting nowThis study compares two ways of giving the drug bimekizumab to people with active psoriatic arthritis or axial spondyloarthritis: as an IV infusion or as a shot under the skin. The goal is to see if the IV method works just as well as the shot. About 392 adults who are suitable f…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with arthritis: drug trial launches
Disease control Recruiting nowThis study tests a drug called bimekizumab in children aged 2 to 17 with specific types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). The goal is to see how the drug moves through the body and if it is safe. About 40 children will take par…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control Recruiting nowThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New lupus drug candidate enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shot aims to keep pericarditis Flare-Ups at bay
Disease control Recruiting nowThis study tests a new drug called KPL-387 in 80 people with well-controlled recurrent pericarditis (inflammation around the heart). The goal is to see if patients can safely switch from their current treatments to KPL-387 alone and still prevent flare-ups. The trial will measure…
Phase: PHASE2 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to tame rare autoimmune disease
Disease control Recruiting nowThis early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Tight-Control strategy tame lupus?
Disease control Recruiting nowThis study tests whether a 'treat-to-target' approach—where doctors adjust treatment every 6 weeks to aim for remission—works better than usual care for people with lupus. About 606 participants who are not in remission will be followed for 120 weeks. The goal is to see if this s…
Phase: NA • Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple ear stimulation device tame psoriatic arthritis?
Disease control Recruiting nowThis study tests whether a non-invasive device that gently stimulates a nerve in the ear can help people with psoriatic arthritis. The device, called taVNS, is used for 20 minutes daily over 10 days. Researchers will measure changes in disease activity, pain, quality of life, and…
Phase: NA • Sponsor: Marmara University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus patients with dangerous low platelet counts
Disease control Recruiting nowThis study tests if the drug sirolimus can help adults with lupus who also have very low platelet counts (a condition called immune thrombocytopenia). Participants will receive either sirolimus or a placebo for 24 weeks, then all will receive sirolimus for another 24 weeks. The g…
Phase: PHASE2, PHASE3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising lupus drug anifrolumab now tested in kids
Disease control Recruiting nowThis phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart drug nicorandil tested as new arthritis treatment
Disease control Recruiting nowThis study tests whether nicorandil, a drug usually used for heart conditions, can reduce inflammation and improve symptoms in people with active rheumatoid arthritis. 46 participants will take nicorandil tablets for 3 months. Researchers will measure joint disease activity and p…
Phase: PHASE3 • Sponsor: Tanta University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New daily pill shows promise for Long-Term psoriatic arthritis control
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a daily ultrasound zap arthritis pain at home?
Disease control Recruiting nowThis study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…
Phase: NA • Sponsor: SecondWave Systems Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Recruiting nowThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gel could heal painful finger sores in rare disease
Disease control Recruiting nowThis early-stage trial tests a new drug called TOP-N53, applied directly to finger ulcers in people with systemic sclerosis (scleroderma). The main goal is to check safety and see if it improves pain and blood flow. Fifteen participants will receive either the drug or a placebo o…
Phase: PHASE2 • Sponsor: Topadur Pharma AG • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kids with gut or joint inflammation get long-term safety check on biologic drug guselkumab
Disease control Recruiting nowThis study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Can a lupus drug help when given early?
Disease control Recruiting nowThis study tests the drug belimumab (Benlysta) in 30 people who were diagnosed with lupus within the last two years. Participants will receive either the drug or a placebo for one year, and then some may switch to placebo in the second year. The goal is to see if early treatment …
Phase: PHASE4 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cell shot aims to tame tough lupus cases
Disease control Recruiting nowThis early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …
Phase: PHASE1 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill could ease juvenile arthritis in kids
Disease control Recruiting nowThis study tests a daily pill called filgotinib in children aged 8 to 17 with a type of arthritis that affects multiple joints. The goal is to see if the drug is safe and helps control the disease over 18 weeks. About 65 participants will take the drug and be monitored for side e…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to cut steroid use in painful rheumatic condition
Disease control Recruiting nowThis Phase 3 trial tests whether adding baricitinib (a JAK inhibitor pill) to standard steroid treatment can help people with polymyalgia rheumatica achieve disease control without needing long-term steroids. About 140 adults aged 50+ with active PMR will receive baricitinib (2 m…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a probiotic tame rheumatoid arthritis? early trial begins
Disease control Recruiting nowThis early-stage study is testing whether an oral probiotic called R-2487 is safe for people with rheumatoid arthritis. Researchers will also check if it reduces joint swelling and inflammation. The trial involves 73 adults with active RA who will take the probiotic and be monito…
Phase: PHASE1 • Sponsor: Rise Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Weight-Loss drug added to arthritis therapy shows promise in new trial
Disease control Recruiting nowThis study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a COPD drug ease rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding roflumilast to standard treatment can reduce joint pain and swelling in people with active rheumatoid arthritis. About 50 adults aged 18-60 will take either roflumilast or a placebo for 12 weeks. Researchers will measure changes in disease activity…
Phase: PHASE2 • Sponsor: Horus University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to stop repeat heart sac inflammation
Disease control Recruiting nowThis study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have sympt…
Phase: PHASE2, PHASE3 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Allergy drug could help rheumatoid arthritis patients
Disease control Recruiting nowThis phase 2 trial is testing whether adding desloratadine, an allergy medication, to standard rheumatoid arthritis therapy can reduce joint inflammation and disease activity. Sixty adults with active RA will receive either desloratadine or a placebo for 12 weeks. The study measu…
Phase: PHASE2 • Sponsor: Horus University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug GS-0151 tested for rheumatoid arthritis in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shoulder implant under Long-Term watch: will it hold up?
Disease control Recruiting nowThis study follows 50 people who receive a Zimmer Biomet shoulder replacement implant to see if it safely improves pain, movement, and quality of life over two years. Participants have shoulder arthritis, fractures, or other joint damage. The main goal is to measure a meaningful …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks ilaris use in rare inflammatory diseases across europe
Disease control Recruiting nowThis study looks at how patients with Familial Mediterranean Fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis and adult-onset Still's disease) use the drug canakinumab (Ilaris) over the long term. Researchers will track 160 patients across Europe …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New RA drug BMS-986454 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called BMS-986454 in 46 adults with rheumatoid arthritis who did not fully respond to methotrexate. The main goal is to check the drug's safety, tolerability, and how it moves through the body. Participants will receive either the drug…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Phase: EARLY_PHASE1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a night-time breathing device boost brain power in older vets with lung and sleep troubles?
Disease control Recruiting nowThis study looks at whether using a positive airway pressure (PAP) machine at night can improve thinking, sleepiness, and quality of life in older veterans (age 60+) who have both COPD and obstructive sleep apnea—a combination called Overlap Syndrome. About 668 participants will …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug trial aims to tame hardening skin and lung damage in scleroderma
Disease control Recruiting nowThis study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New psoriatic arthritis drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether the experimental drug JNJ-88545223 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. About 240 participants will receive either the drug or a placebo to see if it works better than no treatment. The goal is to i…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for indian patients with psoriatic arthritis: guselkumab trial launches
Disease control Recruiting nowThis study tests a drug called guselkumab in 100 Indian adults with psoriatic arthritis, a condition causing joint pain and swelling. Participants must have tried standard treatments without success. The goal is to see if the drug is safe and helps reduce joint symptoms over 12 w…
Phase: PHASE4 • Sponsor: Johnson & Johnson Private Limited • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Ultrasound study to see if guselkumab eases psoriatic arthritis
Disease control Recruiting nowThis study is testing how well the drug guselkumab works for people with psoriatic arthritis, a condition that causes joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 participants over 24 weeks. The goal is to see if guselkumab red…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks arthritis drug persistence in daily life
Disease control Recruiting nowThis study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-w…
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug nipocalimab aims to tame lupus in major trial
Disease control Recruiting nowThis phase 3 study tests whether nipocalimab can help control moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 600 adults will receive either nipocalimab or a placebo, on top of standard treatments. The main goal is to see if more people …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill could ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug reduces joint pain and skin symptoms better than a …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Lupus patients get hope from Cancer-Fighting cell therapy
Disease control Recruiting nowThis early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New study tests belimumab to tame early lupus
Disease control Recruiting nowThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Lupus patients may get new hope from In-Body cell therapy
Disease control Recruiting nowThis early study tests a new treatment called IASO207 for people with active lupus that hasn't responded to standard therapies. The treatment works by creating special immune cells inside the body to target and calm the overactive immune system. The study will check if it's safe …
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug could tame lupus kidney flares
Disease control Recruiting nowThis study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New lupus drug enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see…
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug hopes to ease rare muscle diseases
Disease control Recruiting nowThis Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control Recruiting nowThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One-Time cell therapy could tame tough lupus
Disease control Recruiting nowThis study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Phase: EARLY_PHASE1 • Sponsor: Vivacta Biotechnology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug trial aims to control arthritis in kids
Disease control Recruiting nowThis study is testing a drug called secukinumab, given as an IV infusion, in 20 children aged 2 to 17 with juvenile psoriatic arthritis. The main goals are to see how the drug moves through the body and to check its safety over up to 6 years. This is an early-stage trial, so it f…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New trial aims to solve JIA treatment puzzle after first drug fails
Disease control Recruiting nowThis study is for children aged 2 to 17 with polyarticular juvenile idiopathic arthritis (JIA) whose first TNF inhibitor medication did not work well enough. It compares three different non-TNFi drugs (abatacept, tocilizumab, tofacitinib) against a second TNF inhibitor to see whi…
Phase: PHASE3 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New RA drug JADE201 enters first human safety trial
Disease control Recruiting nowThis early-stage trial tests a single injection of JADE201 in 36 adults with rheumatoid arthritis. The main goal is to check safety and how the body processes the drug. Participants receive either JADE201 or a placebo, and researchers monitor side effects and drug levels in the b…
Phase: PHASE1 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug S-4321 aims to tame overactive immune system
Disease control Recruiting nowThis early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…
Phase: PHASE1 • Sponsor: Seismic Therapeutic AU Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for heart lining pain: can CardiolRx keep flare-ups away?
Disease control Recruiting nowThis study tests whether the drug CardiolRx can prevent another episode of pericarditis (inflammation around the heart) in people who have had repeated attacks. About 110 adults who have been stable on an IL-1 blocker for at least a year will stop that medication and receive eith…
Phase: PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to tame inflammation before stem cell transplant
Disease control Recruiting nowThis phase 2 study tests whether giving emapalumab or a combination of fludarabine and dexamethasone before a stem cell transplant can reduce inflammation and help the donated cells take hold better. The trial involves 39 people with primary immune regulatory disorders or autoinf…
Phase: PHASE2 • Sponsor: Joseph Oved • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Weekly shot aims to tame rare muscle diseases
Disease control Recruiting nowThis study tests anifrolumab, a weekly injection, for adults with moderate to severe polymyositis or dermatomyositis—rare diseases that cause muscle weakness and inflammation. About 240 participants will receive either anifrolumab or a placebo added to their usual care for 52 wee…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowThis study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Donor immune cells aim to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug GT801 tested for tough autoimmune cases
Disease control Recruiting nowThis early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for arthritis sufferers? CIT-013 drug trial begins
Disease control Recruiting nowThis study tests a new drug called CIT-013 in 88 adults with moderately active rheumatoid arthritis. Participants will receive either CIT-013 or a placebo every two weeks for six weeks. The goal is to see if CIT-013 reduces joint swelling and pain better than a placebo, and to ch…
Phase: PHASE2 • Sponsor: Citryll BV • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New study tracks Real-World safety of arthritis and colitis drug in korea
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. Researchers will track side effects and disease activity over 24 weeks. About 2,040 participants are being observed during r…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New arthritis drug trial for kids: could filgotinib help?
Disease control Recruiting nowThis study is testing the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA), a condition causing joint pain and swelling. The goal is to see how the drug moves through the body and if it is safe. Ten children with moderate to severe JIA that is not…
Phase: PHASE1 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for kids with rare arthritis: drug dose study underway
Disease control Recruiting nowThis study is for children and teens aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a condition that causes joint swelling and fever. Researchers are testing different doses of the drug sarilumab to find the best amount that works and is safe. The study involves…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New immune cell combo tackles tough autoimmune diseases
Disease control Recruiting nowThis phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …
Phase: PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Lupus patients may get new hope for blood pressure control
Disease control Recruiting nowThis study tests whether a supplement called 2-HOBA can help people with lupus by lowering blood pressure and reducing harmful immune activity. About 42 women with stable lupus and mild-to-moderate high blood pressure will take either 2-HOBA or a placebo for 8 weeks, then switch.…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for arthritis sufferers: experimental drug GenSci120 enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called GenSci120 in 450 adults with moderate-to-severe rheumatoid arthritis who haven't improved with standard treatments. Participants receive either GenSci120, an existing drug (adalimumab), or a placebo for 14 weeks, followed by an extension period.…
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for heart inflammation sufferers: experimental drug VTX2735 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called VTX2735 in 50 adults with recurrent pericarditis, a condition where the heart's lining becomes inflamed and painful. The goal is to see if the drug is safe and can reduce pain and inflammation. Participants receive different doses over…
Phase: PHASE2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to tame immune system in lupus and Sjogren's
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 2…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of an experimental drug called TLL-018 for people with rheumatoid arthritis. It is for adults who have already finished a previous study of this drug. The goal is to see how well the drug controls arthritis symptoms ov…
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for sarcoidosis patients: drug aims to tame lung inflammation and cut steroids
Disease control Recruiting nowThis study tests an experimental drug called XTMAB-16 in adults with pulmonary sarcoidosis, a condition causing lung inflammation. The goal is to see if the drug is safe and can help patients reduce or stop taking steroids, which have serious side effects. About 94 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Xentria, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Real-world check: does ilaris work safely for rare fever diseases?
Disease control Recruiting nowThis study watches children and adults who are already taking or about to start Ilaris for hereditary periodic fever syndromes or systemic juvenile idiopathic arthritis. Researchers will track side effects and how well the drug controls symptoms over 16 weeks. No new medicine is …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for stubborn arthritis: experimental drug targets immune cells
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in about 37 people whose rheumatoid arthritis has not responded to standard treatments. The goal is to see if the drug is safe and can control the disease by reducing certain immune cells (B cells) that drive inflammation. Pa…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise for rare muscle diseases
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and rashes. Participants who completed a previous study can join. Some will receive the drug via IV every 4 weeks for abo…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could allergy and COPD drugs tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding either roflumilast (a COPD drug) or desloratadine (an allergy drug) to standard rheumatoid arthritis treatment can better control the disease. About 90 adults with active RA will take one of these drugs or a placebo for 12 weeks. The goal is to see…
Phase: PHASE2 • Sponsor: Horus University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lupus drug candidate enters Mid-Stage testing
Disease control Recruiting nowThis Phase 2 clinical trial is testing an investigational drug called SHR-2173 in about 248 adults with active systemic lupus erythematosus (SLE). Participants will receive either the drug or a placebo for 24 weeks, with follow-up. The main goal is to see if SHR-2173 can reduce l…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy targets Hard-to-Treat rheumatoid arthritis
Disease control Recruiting nowThis study tests whether adding tofacitinib to standard methotrexate works better than methotrexate alone for people with active rheumatoid arthritis who have a specific 'myeloid-stromal' type. 130 adults will be randomly assigned to either the combo or methotrexate-only group fo…
Phase: NA • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug targets immune system to tame arthritis
Disease control Recruiting nowThis early-stage trial tests a new medicine called SR-878 in 27 adults with rheumatoid arthritis. The drug works by blocking a protein that controls immune signals. The main goal is to check safety and find a good dose. Participants will be followed for about 16 weeks.
Phase: PHASE1 • Sponsor: SciRhom GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo aims to tame tough autoimmune diseases
Disease control Recruiting nowThis study tests two medications, inebilizumab and blinatumomab, in adults with active lupus (with kidney inflammation) or hard-to-treat rheumatoid arthritis. The goal is to see if these drugs are safe and can help control the diseases. About 220 people will take part. This is no…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a stem cell transplant tame VEXAS syndrome?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a donor can help people with VEXAS syndrome, a rare autoinflammatory disease. Participants receive donor stem cells after drugs to prepare their bone marrow. The goal is to see if the transplant can reverse symptoms and allow p…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests a new medicine called MIL62 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 316 adults with active lupus will receive either MIL62 or a placebo to see if it safely reduces disease activity and allows lower steroid use. The …
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR-T therapy takes on lupus and arthritis
Disease control Recruiting nowThis study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Cord stem cells aim to tame muscle disease and cut steroid use
Disease control Recruiting nowThis study tests whether stem cells from umbilical cord lining can safely reduce symptoms of dermatomyositis and polymyositis, two autoimmune diseases that cause muscle weakness and inflammation. About 40 adults will receive three doses of stem cells or a placebo, then switch. Re…
Phase: PHASE2, PHASE3 • Sponsor: Restem, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Ancient meets modern: can chinese medicine boost standard care for back pain?
Disease control Recruiting nowThis study is testing whether adding traditional Chinese medicine (like herbs or acupuncture) to standard Western treatment helps people with ankylosing spondylitis, a type of arthritis that affects the spine. Researchers will follow 790 patients for 6 months to see if their abil…
Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to shield rheumatoid arthritis patients from heart attacks
Disease control Recruiting nowThis study looks at whether taking tofacitinib (a rheumatoid arthritis drug) along with a statin (a cholesterol-lowering drug) can lower the chance of serious heart problems in people with rheumatoid arthritis. The study will compare this combination to another standard treatment…
Phase: PHASE4 • Sponsor: Shaikh Zayed Hospital, Lahore • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
10-Year checkup: do these shoulder implants hold up?
Disease control Recruiting nowThis study is following 584 people who received Zimmer Biomet shoulder implants to see how well the devices work over 10 years. Participants have shoulder arthritis, fractures, or deformities. Researchers will track implant survival, pain, function, and any side effects. The goal…
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New cell therapy HN2301 enters human trials for autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control Recruiting nowThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Phase: PHASE2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New lupus drug candidate D-2570 enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether the experimental drug D-2570 can help people with active systemic lupus erythematosus (SLE). About 120 adults with moderate-to-severe lupus will be randomly assigned to receive either D-2570 or a placebo. The main goal is to see if D-2570 improves…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill could ease psoriatic arthritis pain in 12 weeks
Disease control Recruiting nowThis study tests an experimental oral drug called D-2570 in 222 adults with active psoriatic arthritis. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see if D-2570 reduces joint tenderness and swelling by at least 20% compared to placebo.
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New lupus drug alnuctamab enters early human testing
Disease control Recruiting nowThis early-stage trial is testing a new drug, alnuctamab, in 21 people with moderate to severe lupus that hasn't improved with standard treatments. The drug is given as an injection under the skin, and participants will stay in the hospital for 9 days after the first dose. The ma…
Phase: PHASE1 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a single infusion of supercharged immune cells tame incurable autoimmune diseases?
Disease control Recruiting nowThis early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …
Phase: NA • Sponsor: LiangZou • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could ease skin tightening in rare disease
Disease control Recruiting nowThis study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rheumatoid arthritis sufferers: experimental drug ELV001 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called ELV001 in people with active rheumatoid arthritis who have not gotten enough relief from standard treatments like methotrexate or TNF inhibitors. About 180 to 220 adults will receive either ELV001 or a placebo added to their current me…
Phase: PHASE2 • Sponsor: Elevara Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with psoriatic arthritis: apremilast trial begins
Disease control Recruiting nowThis Phase 3 study tests whether the drug apremilast (Otezla) can safely reduce joint inflammation and pain in children aged 5 to 17 with active juvenile psoriatic arthritis. About 60 participants will receive either apremilast or a placebo pill for 16 weeks. The main goal is to …
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Seaweed compound could ease arthritis pain in new trial
Disease control Recruiting nowThis study tests whether fucoidan, a substance from brown seaweed, can help adults with active rheumatoid arthritis who haven't improved enough on standard medications. The trial will enroll 40 people and follow them for 12 weeks to see if joint pain and swelling improve. Fucoida…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Tiny early trial launches for new autoimmune drug
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot for lupus enters first human tests
Disease control Recruiting nowThis early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to check safety and side effects. About 112 participants will receive either the drug or a placebo. This…
Phase: PHASE1 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New injection aims to tame rheumatoid arthritis
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from other treatments. The drug is given as a shot under the skin, and the main goal is to see if it's safe and …
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on lupus and scleroderma
Disease control Recruiting nowThis early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Immune cell therapy shows promise for Tough-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug firsekibart takes on anakinra in Still's disease showdown
Disease control Recruiting nowThis study compares two medications, firsekibart and anakinra, to see which works better and is safer for people with Adult-Onset Still's disease (AOSD). The trial will enroll 20 adults aged 18 to 75 who have been diagnosed with AOSD. The main goal is to see how many patients ach…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can East-Meet-West medicine slow spine damage in ankylosing spondylitis?
Disease control Recruiting nowThis study looks at whether combining traditional Chinese medicine with standard Western treatments can better control spine inflammation and slow damage in people with ankylosing spondylitis. About 210 adults aged 18-75 will be followed for up to two years. The goal is to see if…
Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Robot-Assisted knee surgery gets a Real-Time tweak: new study tests flexibility
Disease control Recruiting nowThis study tests whether a surgical robot (ROSA Knee) can help surgeons adjust their knee replacement plan during the operation based on the condition of the patient's soft tissues. About 80 adults with knee arthritis or rheumatoid arthritis will take part and be followed for 2 y…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to save lungs in scleroderma patients
Disease control Recruiting nowThis study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments (like mycophenolate) for people with systemic sclerosis (scleroderma) who also have lung scarring. The trial will enroll 86 adults and follow them for 56 weeks, measuri…
Phase: PHASE3 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New arthritis drug for kids shows promise in early trial
Disease control Recruiting nowThis study is testing a drug called olokizumab in children aged 2 to 18 with active juvenile idiopathic arthritis. The drug is given as a shot under the skin every 4 weeks. Researchers want to see how the drug moves through the body, if it helps control arthritis symptoms, and if…
Phase: PHASE2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a single infusion of modified immune cells tame lupus?
Disease control Recruiting nowThis early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill VENT-03 aims to calm lupus skin flares
Disease control Recruiting nowThis study tests an experimental tablet called VENT-03 for people with active cutaneous lupus erythematosus (CLE), a condition causing painful skin rashes. Twenty-four adults will take either VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researche…
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New study tests rinvoq for psoriatic arthritis spine pain
Disease control Recruiting nowThis study tests whether upadacitinib (Rinvoq), a daily pill, can reduce inflammation in the spine and joints of people with active psoriatic arthritis. About 100 adults who have not responded well to other treatments will receive either the drug or a placebo for 12 weeks. Resear…
Phase: PHASE4 • Sponsor: CARE ARTHRITIS LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New lupus shot aims to tame flares in phase 2 trial
Disease control Recruiting nowThis phase 2 trial tests a new drug called SG301, given as a shot under the skin, for people with systemic lupus erythematosus (SLE). About 120 participants whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo over several months. The g…
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation technique may make stem cell transplants safer for scleroderma patients
Disease control Recruiting nowThis early study tests whether a precise type of total body radiation (IMRT) combined with chemotherapy can safely prepare the body for a stem cell transplant in people with severe systemic sclerosis (scleroderma). The goal is to reduce radiation exposure to the lungs and kidneys…
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug cocktail aims to tame stubborn arthritis
Disease control Recruiting nowThis study is testing whether a combination of two drugs, telitacicept and baricitinib, can help people with difficult-to-treat rheumatoid arthritis. The trial will enroll 30 adults aged 18 to 85 who have not responded to other treatments. Researchers will measure joint swelling …
Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug CPTX2309 enters first human safety trials for arthritis and lupus
Disease control Recruiting nowThis early-stage study tests a new drug, CPTX2309, to see if it is safe and tolerable. It involves 64 healthy adults and people with moderate to severe rheumatoid arthritis or lupus. Researchers will monitor side effects, lab results, and immune responses to determine the drug's …
Phase: PHASE1 • Sponsor: Capstan Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug aims to soften skin and protect lungs in rare disease
Disease control Recruiting nowThis study tests a drug called nemolizumab in 162 adults with systemic sclerosis, a disease that causes skin thickening and can harm internal organs. Participants receive either nemolizumab or a placebo as a shot under the skin for 52 weeks. The main goal is to see if the drug re…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New lupus drug candidate enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called budoprutug (TNT119) in 30 adults with active systemic lupus erythematosus (SLE). The main goal is to check the drug's safety and how the body processes it. Participants will receive a single dose of the drug by IV, and researche…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Arthritis drug xeljanz XR under Real-World watch in korea
Disease control Recruiting nowThis study tracks the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as prescribed by their doctor, and researchers record any s…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a faster steroid taper spare sarcoidosis patients from harmful side effects?
Disease control Recruiting nowThis study compares two steroid-tapering schedules for people with stable sarcoidosis who have been on prednisolone for at least six months. The goal is to see which approach helps more patients cut their dose by at least half without causing a flare-up. Researchers will also mon…
Phase: NA • Sponsor: Royal Brompton & Harefield NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Double-Drug attack on scleroderma: could two immune blockers beat one?
Disease control Recruiting nowThis study tests whether adding two immune-targeting drugs (belimumab and rituximab) to standard mycophenolate can improve skin fibrosis in people with early diffuse systemic sclerosis. Thirty adults with recent-onset disease will receive either the combo or placebo injections fo…
Phase: PHASE2 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibody aims to tame lupus by targeting troublemaking cells
Disease control Recruiting nowThis early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …
Phase: PHASE1 • Sponsor: Hinge Bio • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfen…
Sponsor: University of Patras • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Which drug stops joint damage best in early psoriatic arthritis?
Disease control Recruiting nowThis study tests whether a TNF inhibitor (adalimumab biosimilar) is better than methotrexate at preventing bone damage in people with early psoriatic arthritis. About 108 adults with active disease and symptoms for less than 2 years will be randomly assigned to one of the two dru…
Phase: PHASE4 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot could ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new drug called picankibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. About 222 adults will get either the drug or a placebo for 24 weeks to see if it improves joint swelling and tenderness. The goal is to find…
Phase: PHASE2, PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental CAR-T shot targets three tough autoimmune diseases
Disease control Recruiting nowThis early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Massive study tracks methotrexate in 10,000 arthritis patients
Disease control Recruiting nowThis study is tracking 10,000 Chinese adults with rheumatoid arthritis who are starting or continuing a drug called subcutaneous methotrexate. Researchers want to see how well it works and how safe it is in everyday medical practice, including in patients with additional lung or …
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Robot surgeon takes on knee replacements – will it beat the human hand?
Disease control Recruiting nowThis study compares a robot-assisted system (CORI) to conventional manual instruments for total knee replacement. About 140 participants will be randomly assigned to one of the two methods. The main goal is to see if the robot helps achieve more precise leg alignment after surger…
Phase: NA • Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could biologic drugs offer a better way to treat lupus kidney disease?
Disease control Recruiting nowThis phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The go…
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Exercise may cut heart risk for kidney and arthritis patients
Disease control Recruiting nowThis study tests whether a 6-week aerobic exercise program can reduce cardiovascular risk in people with chronic kidney disease or rheumatoid arthritis. About 90 participants will be assigned to either an exercise program, educational phone calls, or no intervention. Researchers …
Phase: NA • Sponsor: Jérôme Bouchan • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental CAR t therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AFN50 for people with autoimmune diseases that haven't responded to standard therapies. AFN50 is a type of CAR T-cell therapy designed to target and destroy faulty immune cells. The study will enroll 18 adults to check if the tr…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New lupus drug ianalumab tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety of a drug called ianalumab in people with lupus who have already completed a previous study with the same drug. About 550 participants will receive either ianalumab or a placebo monthly or quarterly for up to several years. The main goal…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called Meta10-19 for people with moderate to severe systemic lupus erythematosus (SLE). The therapy uses a patient's own immune cells, modified to better target and destroy faulty B cells that drive the disease. The main goals are to f…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New study tracks xeljanz safety in kids with arthritis
Disease control Recruiting nowThis study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New RA drug enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug, KT501, in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body handles the drug after a single injection. Participants must have had RA for at least 6 months and not responded well …
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to s…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cell therapy takes on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New biologic STR-P004 tested for tough autoimmune cases
Disease control Recruiting nowThis early study tests the safety of a new biologic drug called STR-P004 in 39 adults with autoimmune diseases that have not responded to standard treatments. Participants receive the drug by IV infusion, and researchers monitor for side effects and how the drug behaves in the bo…
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New biologic GR1803 aims to tame lupus in early trial
Disease control Recruiting nowThis study tests a new biologic drug called GR1803 in 44 people with systemic lupus erythematosus, an autoimmune disease. The main goal is to check safety and see if the drug can control lupus activity. Participants must have moderate to severe lupus and have tried standard treat…
Phase: PHASE1, PHASE2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New injection aims to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new injection called AFN50 in 18 adults with autoimmune diseases like lupus. The main goal is to check safety and see how the body reacts, including changes in immune cells. Participants must have active disease despite standard treatments.
Phase: EARLY_PHASE1 • Sponsor: AlphaNa Bioscience Company Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Cosentyx under Real-World watch for kids and adults with skin and joint disease
Disease control Recruiting nowThis study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Immune reset: CAR-T cells take on lupus and more
Disease control Recruiting nowThis early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental cell therapy targets autoimmune diseases that Won't quit
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a psoriasis drug heal these stubborn skin ulcers?
Disease control Recruiting nowThis study tests guselkumab (Tremfya), a drug already used for psoriasis, in 17 adults with pyoderma gangrenosum—a rare disease that leads to painful, hard-to-heal skin ulcers. Participants receive injections every 4 weeks for 28 weeks. Researchers will check if ulcers heal compl…
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on lupus, scleroderma, and Sjogren's
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could CAR-T cells tame tough autoimmune diseases?
Disease control Recruiting nowThis early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects with…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take on lupus in first human test
Disease control Recruiting nowThis early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Diet showdown: mediterranean vs paleo for arthritis relief
Disease control Recruiting nowThis study compares the effects of Mediterranean and Paleolithic diets on rheumatoid arthritis (RA) symptoms, nutrition, and quality of life. Seventy-five adults aged 40-60 with RA will follow one of these diets or their usual diet for 12 weeks. Researchers will measure disease a…
Phase: NA • Sponsor: Kasr El Aini Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Stem cell shot for arthritis knees: hope or hype?
Disease control Recruiting nowThis early study is testing whether a single injection of special stem cells (hiSCs) into the knee joint is safe and can reduce pain and swelling in people with rheumatoid arthritis. Only 15 adults with active knee arthritis will take part. The main goal is to check for side effe…
Phase: NA • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Universal CAR-T cells take on lupus and more in early trial
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study tests secukinumab for back pain patients in korea
Disease control Recruiting nowThis study follows 70 Korean adults with ankylosing spondylitis who have never taken biologic drugs. They will receive secukinumab as part of routine care. Researchers will measure changes in disease activity and inflammation over time to see how effective the treatment is in rea…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lupus drug may be stopped in seniors without flare risk, study tests
Disease control Recruiting nowThis study looks at whether people aged 60 and older with stable lupus can safely stop taking hydroxychloroquine, a common medication that can cause eye damage over time. About 330 participants will either continue the drug or switch to a placebo and be monitored for one year. Th…
Phase: PHASE3 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks Real-World use of psoriatic arthritis drug risankizumab
Disease control Recruiting nowThis study follows about 1,200 people with psoriatic arthritis to see how long they continue taking risankizumab or other advanced treatments in everyday clinical practice. Researchers will track treatment persistence over 24 months. The goal is to understand real-world effective…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Which RA drug keeps patients on board longer? new study aims to find out
Disease control Recruiting nowThis study tracks about 678 adults with moderate to severe rheumatoid arthritis in Germany to see how long they stay on either upadacitinib or TNF inhibitors. Doctors choose the treatment before the study starts, based on standard care. The goal is to learn which drug people stic…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Ultrasound and EMG may tell inflammatory from mechanical shoulder issues
Diagnosis Recruiting nowThis study compares muscle thickness around the shoulder blade in people with early ankylosing spondylitis (an inflammatory condition) versus those with mechanical shoulder blade movement problems. Researchers use ultrasound and electromyography (EMG) to see if they can tell the …
Sponsor: Tanta University • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
New screening tool aims to catch hidden arthritis in psoriasis patients
Diagnosis Recruiting nowThis Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…
Phase: NA • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New scan could reveal hidden organ damage without a biopsy
Diagnosis Recruiting nowThis study tests a radioactive tracer called 124I-AT-01 that binds to amyloid clumps in the body. Researchers want to see if PET/CT scans can detect amyloidosis in organs of people with CAPS who developed it from anakinra injections. Thirty adults will be scanned every 6 months f…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Two cheap blood markers may spot lupus activity early
Diagnosis Recruiting nowThis study looks at whether two simple blood markers—albumin-to-globulin ratio and prognostic nutritional index—can help predict disease activity in people with lupus. Researchers will measure these markers in 200 participants and compare them with standard disease activity score…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New scan could spot hidden heart inflammation early
Diagnosis Recruiting nowThis study is testing whether a special PET/CT scan using a tracer called PentixaFor can accurately detect acute inflammation in the heart. It focuses on three conditions: heart transplant rejection, cardiac sarcoidosis, and myocarditis caused by cancer drugs. Researchers will en…
Phase: PHASE2 • Sponsor: John O. Prior • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Simple cheek swab could predict sudden cardiac death risk
Diagnosis Recruiting nowThis study explores whether a quick, painless cheek swab can spot protein changes linked to inherited heart conditions that cause sudden cardiac death in young people. Researchers will collect samples from 26 patients with arrhythmic disorders or family members at risk. If the te…
Sponsor: St. George's Hospital, London • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Better needle for sarcoidosis diagnosis?
Diagnosis Recruiting nowThis study tests two different needles used during a lung ultrasound procedure to collect tissue samples from swollen lymph nodes. The goal is to see which needle gives better samples for diagnosing sarcoidosis, a disease that causes inflammation. About 128 adults with suspected …
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
Ultrasound may replace costly CT scans for lung disease in arthritis patients
Diagnosis Recruiting nowThis study tests whether a quick, non-invasive lung ultrasound can detect interstitial lung disease in people with rheumatoid arthritis. About 280 adults with RA and risk factors for lung disease will get an ultrasound, and results will be compared to standard chest CT scans. If …
Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
New scan could shine a light on hidden inflammation
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called [18F]AlF-FAPI-74 for PET/CT scans to see if it can find inflammation better than the current standard tracer. The trial will involve 140 people with fever of unknown origin, IgG4-related disease, or axial spondylarthritis. Res…
Phase: PHASE2, PHASE3 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Diagnosis
Last updated Jun 27, 2026 12:09 UTC
-
New handheld scanner could replace MRI for muscle disease monitoring
Diagnosis Recruiting nowThis study is testing a handheld device called mScan that uses a tiny, painless electrical current to measure muscle health. Researchers want to see if it can give similar results to an MRI, but faster and more conveniently. The study involves 150 adults with and without muscle d…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
Could a cancer imaging agent spot hidden heart inflammation?
Diagnosis Recruiting nowThis study is testing whether a radioactive tracer called Tc 99m tilmanocept, already used in other imaging, can help detect cardiac sarcoidosis—a condition where inflammation forms in the heart. Researchers will give the tracer to 15 adults with confirmed sarcoidosis and take sp…
Phase: PHASE2 • Sponsor: Duke University • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Neck scan could predict heart attacks in arthritis patients
Prevention Recruiting nowThis study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…
Phase: PHASE4 • Sponsor: Instituto de Investigación Marqués de Valdecilla • Aim: Prevention
Last updated Jun 27, 2026 12:39 UTC
-
Breakthrough trial aims to prevent arthritis in psoriasis patients
Prevention Recruiting nowThis study tests whether the drug guselkumab can prevent psoriatic arthritis in people with psoriasis who are at high risk. 176 adults with psoriasis and early signs of joint inflammation will receive either guselkumab or standard care. The goal is to see if the drug can stop art…
Phase: PHASE4 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Can the shingles vaccine protect those with autoimmune conditions?
Prevention Recruiting nowThis study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Shingles vaccine put to the test in frail patients
Prevention Recruiting nowThis study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
Diet showdown: three eating plans battle bloating in scleroderma patients
Symptom relief Recruiting nowThis study compares three different diets to see which one best reduces bloating and other stomach symptoms in people with systemic sclerosis (scleroderma). Sixty participants will follow one of three diets for six weeks: a low-FODMAP diet, a diet that removes foods harmful to th…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Diet showdown: Gluten-Free vs. mediterranean for arthritis relief
Symptom relief Recruiting nowThis study looks at whether changing what you eat can help with rheumatoid arthritis. 66 adults with RA will follow either a gluten-free diet, a Mediterranean diet, or their usual diet for 12 weeks. Researchers will measure disease activity, quality of life, and inflammation to s…
Phase: NA • Sponsor: Hasan Kalyoncu University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Can a smarter oxygen device help lung disease patients move more?
Symptom relief Recruiting nowThis study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Nerve block injection may ease back pain in ankylosing spondylitis patients
Symptom relief Recruiting nowThis study tests whether a single nerve block injection (erector spinae plane block) can reduce persistent back pain in people with ankylosing spondylitis whose disease activity is already controlled by medication. Fifteen adults aged 18–65 will receive the injection and be monit…
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can facial exercises ease the stiffness of scleroderma?
Symptom relief Recruiting nowThis study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to ease chronic pain without pills for military personnel
Symptom relief Recruiting nowThis study is testing two holistic, non-drug programs to help military members manage chronic musculoskeletal pain. About 608 participants will be randomly assigned to either a single-session class called Empowered Relief, a multi-session program called Move to Health, or usual c…
Phase: NA • Sponsor: Brooke Army Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New needle technique aims to ease back pain in ankylosing spondylitis
Symptom relief Recruiting nowThis study tests a new, ultrasound-guided acupotomy technique to improve symptoms in people with ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. About 60 adults with active disease will receive the treatment to see if it reduces pain and improves …
Phase: NA • Sponsor: China-Japan Friendship Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Can a one-hour class beat eight weeks of therapy for chronic pain?
Symptom relief Recruiting nowThis study compares two online treatments for chronic pain: an 8-week cognitive behavioral therapy program (16 hours total) and a single 2-hour pain relief skills class. Researchers want to see which works better for reducing pain intensity and interference. The study will enroll…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New zoom therapy aims to ease chronic pain without drugs
Symptom relief Recruiting nowThis study tests a short behavioral treatment delivered over Zoom to help adults with fibromyalgia, lupus, chronic pelvic pain, or chronic low back pain. The goal is to reduce pain, disability, and related issues like anxiety or depression. Participants will learn strategies to m…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New study tests online fatigue programs for lupus patients
Symptom relief Recruiting nowThis study tests whether online group programs to manage fatigue can help people with lupus. Participants will either receive a fatigue booklet alone or also attend online group sessions (4 or 7 weeks long). The goal is to see if the programs reduce fatigue impact and improve qua…
Phase: NA • Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Mediterranean diet may ease arthritis in kids
Symptom relief Recruiting nowThis study looks at whether a Mediterranean-style diet can improve arthritis symptoms in children by changing the bacteria in their gut. Fifty-four children aged 8-18 with juvenile idiopathic arthritis will follow the diet for 8 weeks, with an option to continue for 4 more weeks.…
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Could a simple injection melt away painful calcium deposits?
Symptom relief Recruiting nowThis study tests whether injecting sodium thiosulfate directly into painful calcium deposits (calcinosis) can shrink them and ease symptoms. Twenty adults with scleroderma, dermatomyositis, or mixed connective tissue disease will receive ultrasound-guided injections. The main goa…
Phase: PHASE2 • Sponsor: Robyn T. Domsic, MD, MPH • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New online program aims to boost brain health in teens with lupus
Symptom relief Recruiting nowThis study is testing a new telehealth program designed to support brain health in teenagers with childhood-onset lupus. The program teaches problem-solving, emotion regulation, and communication skills over 10 online sessions. Researchers want to see if the program is practical …
Phase: NA • Sponsor: Andrea Knight • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Mindfulness may ease sarcoidosis fatigue in new virtual trial
Symptom relief Recruiting nowThis study tests whether an 8-week virtual Mindfulness-Based Stress Reduction (MBSR) program can reduce fatigue, anxiety, and depression in 100 adults with sarcoidosis. One group takes MBSR; the other joins a monthly virtual support group. Researchers will compare which approach …
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Weight loss drug ozempic tested in lung disease patients
Symptom relief Recruiting nowThis pilot study tests whether semaglutide (Ozempic), a drug used for diabetes and obesity, is safe and tolerable for weight loss in people with advanced lung disease. Eight participants with conditions like COPD or pulmonary fibrosis will take weekly injections for 12 weeks. Res…
Phase: PHASE1, PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Meat or fat? diet study aims to tame IBD and arthritis symptoms
Symptom relief Recruiting nowThis study tests whether a ketogenic (low-carb, high-fat) or carnivore (all meat) diet can improve quality of life and reduce symptoms in adults with inflammatory bowel disease (Crohn's or ulcerative colitis) or rheumatoid arthritis. Participants are randomly assigned to one of t…
Phase: NA • Sponsor: Fuller Research Foundation • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Hope for rare bone and skin condition: new drug trial launches
Symptom relief Recruiting nowThis study tests whether etanercept, a drug that blocks inflammation, can reduce pain and disease activity in adults with SAPHO syndrome—a rare condition affecting bones, joints, and skin. Participants must have tried standard treatments like NSAIDs without enough relief. The tri…
Phase: PHASE2, PHASE3 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Pill or shot? new study seeks best way to tame RA flares
Symptom relief Recruiting nowThis study tests whether a single steroid injection works as well as a three-week course of steroid pills for treating rheumatoid arthritis flares. Researchers will track how patients feel, their ability to function, and their satisfaction with treatment. The goal is to help pati…
Phase: PHASE4 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Walking away arthritis pain: study tests best exercise dose
Symptom relief Recruiting nowThis study looks at how three different levels of physical activity—45, 90, or 150 minutes per week—affect arthritis symptoms like pain and mobility. Researchers will enroll 285 adults with arthritis, rheumatoid arthritis, gout, fibromyalgia, osteoarthritis, or lupus. Participant…
Phase: NA • Sponsor: University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Can video exercise sessions ease back pain? new study tests remote rehab for stiff spines
Symptom relief Recruiting nowThis study tests whether live or pre-recorded video exercise programs help people with ankylosing spondylitis (a chronic spine condition) feel better and move easier. About 66 adults will do exercises three times a week for 8 weeks, either via live video, recorded video, or a sim…
Phase: NA • Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Robot vs. navigation: which knee surgery is better?
Symptom relief Recruiting nowThis study compares two types of computer-assisted knee replacement surgery: one using a navigation system (OrthoPilot) and one using a robotic arm (MAKO). The goal is to see if they provide similar improvements in knee function and pain relief one year after surgery. About 140 a…
Sponsor: Aesculap AG • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New pill offers hope for fingers that turn white and blue in the cold
Symptom relief Recruiting nowThis study tests an oral pill called treprostinil in 30 adults with severe Raynaud's phenomenon that hasn't improved with usual therapies. Raynaud's causes fingers and toes to change color and become painful when cold or stressed. Participants will take the pill three times daily…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New RA drug LFD-200 enters early human testing
Symptom relief Recruiting nowThis early-stage study tests a new drug called LFD-200 in healthy volunteers and people with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body processes the drug. Researchers will give single or multiple doses and watch for side effec…
Phase: PHASE1 • Sponsor: Lifordi Immunotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Plant-Based diet trial aims to calm arthritis pain
Symptom relief Recruiting nowThis study tests whether a 16-week plant-based diet can reduce disease activity and improve quality of life in 180 adults with rheumatoid arthritis. Participants receive weekly food boxes, diet guidance, and cooking classes, while a control group continues their usual diet. The g…
Phase: NA • Sponsor: Center for Clinical Research and Prevention • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a home workout program help early arthritis patients?
Symptom relief Recruiting nowThis pilot study is testing whether a remotely-delivered exercise program is practical and acceptable for people recently diagnosed with rheumatoid arthritis (within 6 months). Fifteen participants will receive intensive aerobic and resistance training via video calls. The main g…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New support program aims to help caregivers of frail seniors with arthritis
Symptom relief Recruiting nowThis study tests a new program called INSPIRE, designed to support informal caregivers (like family or friends) of older adults with rheumatoid arthritis and frailty. The program involves three sessions with a healthcare professional over 12 weeks, focusing on emotional support, …
Phase: NA • Sponsor: Glostrup University Hospital, Copenhagen • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Stress relief: could a simple hormone boost ease fatigue in PMR/GCA patients?
Symptom relief Recruiting nowThis study looks at whether taking extra hydrocortisone during times of mild to moderate stress (physical or mental) can improve health-related quality of life, especially fatigue, in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) who are on long-term, low…
Phase: PHASE4 • Sponsor: Marianne Christina Klose • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Simple breathing trick may ease stiff spine symptoms
Symptom relief Recruiting nowThis study tests whether adding deep breathing exercises to core stability exercises can improve lung function and physical ability in people with ankylosing spondylitis (AS). AS is a type of arthritis that mainly affects the spine, causing pain, stiffness, and sometimes trouble …
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Lupus secrets revealed: major study tracks disease over time
Knowledge-focused Recruiting nowThis study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch deep dive into mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) by observing up to 2,000 participants over time. Researchers will collect medical history, blood samples, and genetic data to identify …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
20,000 volunteers needed to decode immune disease genetics
Knowledge-focused Recruiting nowThis study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists seek genetic clues to mysterious fever diseases
Knowledge-focused Recruiting nowThis study aims to learn more about the genetics and natural history of autoinflammatory diseases, which cause repeated fevers and inflammation. Researchers will study up to 5,000 people, including patients, their relatives, and healthy volunteers. Participants provide blood and …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
500-Person biobank aims to unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists track spondyloarthritis in families to uncover clues to severe disease
Knowledge-focused Recruiting nowThis study follows up to 2,000 people with spondyloarthritis (a group of inflammatory joint and spine conditions) and their healthy relatives. Researchers aim to identify symptoms, genetic factors, and medical tests that predict who will develop more severe forms of the disease. …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New biomarker study aims to spot lupus kidney disease earlier
Knowledge-focused Recruiting nowThis study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Lupus drug anifrolumab under pregnancy safety spotlight
Knowledge-focused Recruiting nowThis study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to unlock secrets of systemic sclerosis through patient samples
Knowledge-focused Recruiting nowThis study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of muscle inflammation
Knowledge-focused Recruiting nowThis study aims to collect medical information and tissue samples from 500 people with suspected or confirmed inflammatory muscle diseases, as well as healthy volunteers. Researchers will use blood, muscle, and skin samples to study what causes these diseases and how they progres…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Lupus drug in breast milk: new study aims to find out
Knowledge-focused Recruiting nowThis study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study hopes to find a simple test for MS diagnosis
Knowledge-focused Recruiting nowThis study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Could a Finger-Prick test replace clinic blood draws for arthritis patients?
Knowledge-focused Recruiting nowThis study is testing a new device called BloodTrackR that lets people with rheumatoid arthritis collect a small blood sample at home using a finger prick and a smartphone app. Twenty participants will try the device and answer questions about how easy it is to use. The goal is t…
Sponsor: University of Ulster • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
NIH launches major study to uncover why rheumatic diseases hit minorities harder
Knowledge-focused Recruiting nowThis study aims to learn more about the causes of rheumatic diseases—conditions that cause joint pain, stiffness, and swelling—and why they often affect minority groups more severely. Researchers will observe up to 7,500 adults with known or suspected rheumatic disease, providing…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lupus patients enrolled in major Long-Term observation study
Knowledge-focused Recruiting nowThis study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can your genes predict eye damage from a common arthritis drug?
Knowledge-focused Recruiting nowThis study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Major study aims to uncover hidden heart disease and test steroid treatment
Knowledge-focused Recruiting nowThis study is tracking 1,500 people with cardiac sarcoidosis—a condition where inflammation affects the heart—to learn how doctors currently diagnose and treat it. Researchers will also test whether corticosteroid therapy improves outcomes. The goal is to create better guidelines…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lupus drug anifrolumab under scrutiny in pregnancy safety study
Knowledge-focused Recruiting nowThis study follows 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab (Saphnelo) during pregnancy affects the health of mothers or their babies. Researchers will compare women who took the drug during pregnancy to those who did not, tracking bi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Arthritis drug may mask diabetes, study warns
Knowledge-focused Recruiting nowThis study looks at whether sulfasalazine, a drug for inflammatory arthritis, makes the standard diabetes blood test (HbA1c) falsely low. That could mean diabetes goes undiagnosed or is undertreated in these patients. Researchers will use continuous glucose monitors and fasting b…
Sponsor: Klavs Würgler Hansen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to crack Tough-to-Diagnose joint diseases
Knowledge-focused Recruiting nowThis study is collecting joint fluid and tissue samples from 50 adults with inflammatory or non-inflammatory bone and joint diseases. Researchers will use both standard and advanced lab techniques to find new biomarkers that could help diagnose rheumatic diseases more accurately …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lupus drug anifrolumab under safety microscope: does it raise infection or cancer risk?
Knowledge-focused Recruiting nowThis study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can we predict the best RA drug? new study seeks answers
Knowledge-focused Recruiting nowThis study is looking for clues to predict how well different rheumatoid arthritis (RA) drugs will work in individual patients. Researchers will give 400 adults with RA one or more standard medications and track their response over 16 weeks. The goal is to find genetic or other f…
Phase: PHASE3 • Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare bone disease under the microscope: what causes melorheostosis?
Knowledge-focused Recruiting nowThis study follows adults with melorheostosis, a rare disease that causes bone thickening, pain, and joint problems. Researchers will track how the disease progresses over time, collect genetic samples from patients and their relatives, and look for biomarkers. The goal is to bet…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for lung disease genes in 3,500 volunteers
Knowledge-focused Recruiting nowThis study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
10,000 joint replacements under the microscope: what makes an implant last?
Knowledge-focused Recruiting nowThis study collects information from 10,000 adults who have had hip or knee replacement surgery at Heidelberg University Hospital. Researchers will follow participants during routine check-ups to see how long the artificial joints last, how well they function, and what problems m…
Sponsor: University Hospital Heidelberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Could your environment trigger this rare muscle disease?
Knowledge-focused Recruiting nowThis study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can an arthritis drug also help fatty liver? new study investigates.
Knowledge-focused Recruiting nowThis study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechani…
Phase: NA • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive study tracks lung disease progression in 4,000 patients
Knowledge-focused Recruiting nowThis study follows 4,000 people with interstitial lung disease (including conditions like pulmonary fibrosis and sarcoidosis) to understand how the disease naturally changes over time. Researchers will collect medical data and blood samples, and compare them to a healthy control …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Lupus Patients' shingles vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Smartphone addiction may worsen neck problems in arthritis patients
Knowledge-focused Recruiting nowThis study looks at how heavy smartphone use impacts neck posture, muscle strength, balance, and tongue pressure in people with rheumatoid arthritis or ankylosing spondylitis. Researchers will compare these patients to healthy individuals to separate the effects of the disease fr…
Sponsor: Merve Şahin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to uncover why RA patients struggle to swallow
Knowledge-focused Recruiting nowThis study looks at why people with rheumatoid arthritis (RA) may have trouble swallowing. Researchers will use a small, flexible camera to examine the throat and voice box in 137 adults with RA. They aim to find factors that predict swallowing difficulty and see if joint problem…
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New navigation tech aims to improve hip replacement accuracy
Knowledge-focused Recruiting nowThis study looks at how well a non-invasive navigation system helps surgeons place the hip cup during total hip replacement. About 118 people with hip conditions like arthritis or hip dysplasia will take part. The goal is to see if the actual cup position matches the planned posi…
Phase: NA • Sponsor: DePuy Orthopaedics • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
High-Tech insoles aim to ease arthritis foot pain
Knowledge-focused Recruiting nowThis study aims to create better custom insoles for people with rheumatoid arthritis who have foot pain. Researchers will use CT scans and motion analysis to build a digital model of how feet move and apply pressure. The goal is to design insoles that reduce pain and improve comf…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
NIH launches major study to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to simplify diagnosis of autoimmune platelet disorder
Knowledge-focused Recruiting nowThis study is testing whether a specialized blood test (MAIPA) can accurately identify autoimmune thrombocytopenia (ITP) in patients with low platelet counts. Currently, ITP is diagnosed by ruling out other causes, which can be slow and uncertain. Researchers will collect blood s…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study aims to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study is looking at 50 children and adults with rare autoinflammatory diseases—conditions where the immune system causes inflammation without a clear reason. Researchers want to find what leads to a faster diagnosis, what factors are linked to these diseases, and which treat…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a simple walking test help kids with arthritis move better?
Knowledge-focused Recruiting nowThis study is testing whether a walking test called the Dynamic Gait Index (DGI) is a reliable way to measure walking difficulties in children with juvenile idiopathic arthritis (JIA). Researchers will compare 26 children with JIA to 26 healthy children, all aged 8-16. The goal i…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Double breathing trouble: study tests two therapies to protect hearts
Knowledge-focused Recruiting nowThis study looks at how having both sleep apnea and COPD (called overlap syndrome) affects the heart. Researchers will compare people with one or both conditions and test two breathing treatments—a special mask that helps breathing at night and extra oxygen—to see which may impro…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists dig into immune signals to unlock psoriasis mystery
Knowledge-focused Recruiting nowThis study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Glowing dye reveals hidden clues in rheumatoid arthritis
Knowledge-focused Recruiting nowThis study tests a special dye and camera to look at lymph vessels in the hands of people with rheumatoid arthritis. The dye is injected into the skin and glows under a near-infrared camera, allowing researchers to see how lymph fluid moves. The goal is to better understand how t…
Phase: PHASE1 • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Lupus drug anifrolumab under scrutiny for pregnancy risks
Knowledge-focused Recruiting nowThis study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can we predict chronic pain in teens? new study seeks answers
Knowledge-focused Recruiting nowThis study looks at 600 teens and young adults (ages 14-26) with conditions like juvenile arthritis, fibromyalgia, or past surgeries to understand why some develop long-lasting pain while others don't. Researchers will examine pain sensitivity, immune markers, and social factors …
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists launch major study to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of Common Variable Immunodeficiency (CVID) and related inborn errors of immunity. Researchers will observe up to 500 patients over time using blood tests, imaging, and other exams. The goal is to find better ways to diagnos…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study seeks to predict rheumatoid arthritis flares using simple blood tests
Knowledge-focused Recruiting nowThis study looks at 200 adults with well-controlled rheumatoid arthritis to find ways to predict when a disease flare might occur. Researchers will track symptoms and check blood markers every 3 months. The goal is to help doctors adjust treatment early and prevent flares.
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New tool aims to help melanoma patients with autoimmune conditions navigate treatment decisions
Knowledge-focused Recruiting nowThis study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Could iron be the key to understanding lupus?
Knowledge-focused Recruiting nowThis study looks at how a type of cell death called ferroptosis, which is driven by iron, might play a role in lupus. Researchers will take blood samples from 120 people with lupus and compare them to people with other autoimmune diseases. The goal is to find new clues for future…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Could weak legs be making it hard to breathe? new study investigates
Knowledge-focused Recruiting nowThis study looks at why people with interstitial lung disease (ILD) often feel breathless and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 ILD patients and test how extra oxygen affects …
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
500-Patient study aims to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 500 children and adults with rare genetic disorders called type I interferonopathies, which cause severe inflammation and neurological problems. Researchers will track how the disease progresses over time and look for biological markers to improve diagnosis and…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to unlock secrets of rare VEXAS syndrome
Knowledge-focused Recruiting nowThis study is building a national registry of 500 adults with VEXAS syndrome, a rare inflammatory disease. Researchers will collect medical information and biological samples during routine care to learn more about how the disease behaves, what treatments work best, and how to di…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could a common arthritis drug harm nerves? new study investigates.
Knowledge-focused Recruiting nowThis study will use nerve conduction tests to check for nerve damage in 60 adults with rheumatoid arthritis. Half are taking baricitinib (Olumiant), a JAK inhibitor, and the other half are on standard disease-modifying drugs. The goal is to see if baricitinib is linked to a highe…
Phase: NA • Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to unlock secrets of rare skin disease morphea
Knowledge-focused Recruiting nowThis study is creating a registry of 500 children and adults with morphea (localized scleroderma) to track how the disease behaves over time, what complications arise (like arthritis), and whether it has an autoimmune cause. Participants provide medical history and skin assessmen…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New gadget aims to take the guesswork out of measuring skin hardening in scleroderma
Knowledge-focused Recruiting nowThis study is testing a new device called ADHELASKIN to see if it can measure skin stiffness more accurately than the current method (feeling the skin by hand) in people with systemic sclerosis (scleroderma). The study will compare 100 participants: those with scleroderma and hea…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Scientists probe hidden clot risks in autoimmune skin disorders
Knowledge-focused Recruiting nowThis study looks at blood clotting in people with autoimmune skin diseases like bullous pemphigoid and lupus. Researchers will collect blood samples from 39 participants—some with active disease and some with mild or controlled disease—plus 15 healthy controls. They will measure …
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can we predict RA flares? new study watches remission patients for clues
Knowledge-focused Recruiting nowThis study follows 200 adults with rheumatoid arthritis who are already in stable remission from standard medications. Researchers will track their health over up to 5 years using exams, ultrasound, and X-rays to see who stays well and who has a flare. The goal is to learn how to…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can shedding pounds calm psoriatic arthritis? new study investigates
Knowledge-focused Recruiting nowThis study looks at how weight loss (using tirzepatide) and a biologic drug (ixekizumab) affect the body in people with psoriatic arthritis who are overweight or obese. About 45 adults will receive one or both treatments. Researchers will take samples of skin, joint tissue, and f…
Phase: NA • Sponsor: NHS Greater Glasgow and Clyde • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
100,000 volunteers needed to unlock secrets of chronic diseases
Knowledge-focused Recruiting nowThis study is collecting health information, lifestyle data, and biological samples from up to 100,000 adults to help researchers better understand diseases like lupus, celiac disease, and kidney disease. Participants provide data and samples through a direct-to-patient platform.…
Sponsor: Joined Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive lung disease registry aims to unlock secrets of progressive fibrosis
Knowledge-focused Recruiting nowThis registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive biobank launches to unlock secrets of chronic inflammation
Knowledge-focused Recruiting nowThis study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study tests simple tools to boost COVID-19 shots in minority communities with arthritis
Knowledge-focused Recruiting nowThis study tests whether watching videos about COVID-19 vaccination experiences and receiving phone support can increase vaccine uptake among Black and Latinx adults with rheumatic diseases. Researchers will enroll 1,170 participants from rheumatology clinics. The goal is to find…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to cut risky pills for seniors with arthritis
Knowledge-focused Recruiting nowThis study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a 14-Day trial boost app use for back pain patients?
Knowledge-focused Recruiting nowThis study looks at how to make it easier for people with axial spondyloarthritis to start using the Axia app. Two groups of 200 participants will get different onboarding brochures: one with standard instructions and one with a 14-day free trial. Researchers will track how many …
Phase: NA • Sponsor: Wuerzburg University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can we predict lung trouble in arthritis patients?
Knowledge-focused Recruiting nowThis study looks at 750 people with rheumatoid arthritis (RA) who are 45 or older to find early signs of interstitial lung disease (ILD), a serious lung complication. Researchers will use CT scans and track changes over 3-5 years to identify risk factors. The goal is to better un…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple blood test predict arthritis drug success?
Knowledge-focused Recruiting nowThis study is testing whether a mathematical model using blood markers can predict how well rheumatoid arthritis patients will respond to a lower dose of the drug rituximab. Thirty adults with RA who already do well on standard-dose rituximab will switch to a lower dose. Research…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Lupus researchers probe immune cell signals for clues
Knowledge-focused Recruiting nowThis study looks at specific immune cells (iNKT cells and monocytes) in people with lupus to see how certain receptors on these cells change when the disease is active versus stable. Researchers will collect extra blood samples from 50 lupus patients during routine visits. The go…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Heart disease detective: 1,000-Person study hunts for hidden genetic triggers of sudden cardiac death
Knowledge-focused Recruiting nowThis study is looking for new genes and blood markers linked to arrhythmogenic cardiomyopathy (AVC), a genetic heart condition that can lead to heart failure and sudden cardiac arrest. Researchers will enroll 1,000 people, including patients with AVC or unexplained cardiac arrest…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New study tracks psoriatic arthritis patients to predict joint damage
Knowledge-focused Recruiting nowThis study follows 425 adults with recent psoriatic arthritis (PsA) for up to 10 years to see how many develop joint damage and what factors predict it. Researchers will use X-rays and other data to identify early signs of aggressive disease. The goal is to help doctors decide wh…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Researchers hunt for blood clues to predict arthritis Flare-Ups
Knowledge-focused Recruiting nowThis study looks at 200 adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis to see if certain blood markers (related to oxidative stress) can help doctors monitor how the disease changes over a year. Participants give blood samples at the start, 6 mon…
Sponsor: University of Thessaly • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New scan could reveal hidden heart inflammation in common heart failure
Knowledge-focused Recruiting nowThis study is testing a special PET scan that uses a tracer called 68Ga-FAPI to look for inflammation and scarring in the hearts of people with a specific type of heart failure (HFpEF). About 35 adults with this condition will get the scan to see how well it works. The goal is to…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Heart scans aim to spot hidden risks in kids with lupus
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound. The goal is to identify which children are at higher risk for heart issues. No new treatments are being tested.
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New study seeks early warning signs for pregnancy complications in lupus patients
Knowledge-focused Recruiting nowThis observational study is following 700 pregnant women with lupus or antiphospholipid syndrome across nine medical centers. Researchers are looking at specific proteins in the blood to see if they can predict serious pregnancy complications like fetal death, preterm delivery, o…
Sponsor: Hospital for Special Surgery, New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Researchers probe pain pathways in two common chronic conditions
Knowledge-focused Recruiting nowThis study looks at how pain is processed in people with fibromyalgia and rheumatoid arthritis, two conditions that cause long-term pain. Researchers will measure pressure pain thresholds in 150 adults to compare pain mechanisms. The goal is to better understand the differences a…
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can better transition programs keep young rheumatic patients healthy?
Knowledge-focused Recruiting nowThis study looks at young adults with chronic inflammatory rheumatic diseases who are moving from pediatric to adult healthcare. Researchers want to see if a structured program that includes education workshops and joint doctor visits helps patients manage their own care better. …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Blood and AI join forces to catch lung scarring early in rheumatic disease patients
Knowledge-focused Recruiting nowThis study aims to find better ways to detect lung scarring (interstitial lung disease) early in people with connective tissue diseases like scleroderma or rheumatoid arthritis. Researchers will analyze tiny particles in the blood called extracellular vesicles and use AI to exami…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scalp scans may reveal hidden clues in scleroderma patients
Knowledge-focused Recruiting nowThis study looks at whether a simple, non-invasive scalp exam called trichoscopy can help predict how severe systemic scleroderma is and whether it affects internal organs. Researchers will compare scalp images from 200 scleroderma patients and healthy volunteers. The goal is to …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for cherubism genes in 600-Person study
Knowledge-focused Recruiting nowThis study aims to find the genes and DNA changes that cause cherubism, a rare condition that affects the jaw bones. Researchers will study blood and tissue samples from up to 600 people, including patients and their family members. The long-term goal is to understand the disease…
Sponsor: UConn Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gene-Modified cell therapy: researchers track Long-Term safety in arthritis and skin disease patients
Knowledge-focused Recruiting nowThis study monitors 36 people who previously received an experimental gene-modified regulatory T cell (Treg) therapy for rheumatoid arthritis or hidradenitis suppurativa. The goal is to check for any delayed side effects and see how long the modified cells last in the body. Parti…
Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Massive lupus registry launches to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Large study tracks spine disease progression in thousands of chinese patients
Knowledge-focused Recruiting nowThis study follows 2250 Chinese adults with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) to see how their condition changes over time. Researchers will measure physical function, spinal damage on X-rays, and episodes of eye inflammation. The goal…
Sponsor: China-Japan Friendship Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists probe hidden pain pathways in arthritis
Knowledge-focused Recruiting nowThis study aims to better understand why people with inflammatory arthritis experience chronic pain. Researchers will look at how the brain processes pain and how it affects daily life. 350 adults starting or switching arthritis medications will be followed over time. The goal is…
Sponsor: Diakonhjemmet Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New study probes painful joint side effects of immunotherapy
Knowledge-focused Recruiting nowThis study aims to understand how rheumatic side effects (like arthritis) from cancer immunotherapy affect patients' daily lives. Researchers will interview 20 adults who have experienced these side effects to learn about their severity and impact. The goal is to improve future c…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists seek clues to mysterious childhood fever syndrome
Knowledge-focused Recruiting nowThis study aims to learn more about PFAPA, a condition that causes repeated fevers, sore throats, and mouth sores in children. Researchers will collect blood, saliva, stool, and tonsil tissue from 1,500 people with PFAPA or other tonsil problems. No treatment is given; the goal i…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Simple tests could revolutionize chronic pain diagnosis
Knowledge-focused Recruiting nowThis study aims to improve how doctors diagnose and treat chronic muscle and joint pain by using simple questionnaires and pain sensitivity tests. Researchers will study 250 adults with conditions like osteoarthritis, fibromyalgia, chronic low back pain, or inflammatory arthritis…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Massive study aims to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study is for people with certain autoinflammatory diseases (like NOMID, DIRA, CANDLE, SAVI, and others) and their healthy relatives. Researchers want to learn more about what causes these diseases and how they affect the body over time. Participants will have medical tests a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to take the guesswork out of treating Kids' pain
Knowledge-focused Recruiting nowThis observational study is working to create a more objective way to measure pain in children with juvenile idiopathic arthritis, lupus, or fibromyalgia. Researchers will follow 90 participants for one year, collecting data during regular clinic visits. The goal is to develop a …
Sponsor: Children's National Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Scientists dive deep into joint tissue to unlock secrets of rare arthritis
Knowledge-focused Recruiting nowThis study aims to better understand rare forms of inflammatory arthritis, including those linked to other autoimmune diseases or cancer immunotherapy. Researchers will analyze joint tissue samples from 100 adults to compare the immune cells and molecules involved. The goal is to…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
New study aims to decode back pain in ankylosing spondylitis patients
Knowledge-focused Recruiting nowThis study looks at different types of low back pain in people with ankylosing spondylitis, a type of arthritis that mainly affects the spine. Researchers want to see how these pain types relate to daily function and quality of life. The study will involve 200 adults with ankylos…
Sponsor: Konya Beyhekim Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Massive new registry aims to unlock secrets of swallowing disorders
Knowledge-focused Recruiting nowThis study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
200 RA patients join study to unlock secrets of treatment resistance
Knowledge-focused Recruiting nowThis study will follow 200 adults with rheumatoid arthritis (RA) that does not respond well to standard treatments, known as refractory RA. The goal is to learn more about why some people have hard-to-treat RA and find clues to better personalize their care. Participants will be …
Sponsor: Peking University Third Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Largest skin lupus database aims to uncover disease patterns
Knowledge-focused Recruiting nowThis study is building a database of 700 people with cutaneous lupus erythematosus (CLE) to track how often it occurs and how severe it gets. Researchers at the University of Pennsylvania and UT Southwestern are collecting information over time. No new treatments are being tested…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New database study aims to better understand dermatomyositis skin symptoms
Knowledge-focused Recruiting nowThis study collects information from people with dermatomyositis to better understand how the disease affects their skin and quality of life. Researchers will use a special scoring tool called CDASI to measure skin changes over time. The goal is to improve knowledge about the dis…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Could palliative care ease the burden of arthritis? new study seeks answers
Knowledge-focused Recruiting nowThis study looks at whether palliative and supportive care, usually given to people near the end of life, could also help those with long-term inflammatory arthritis like rheumatoid arthritis. Researchers will interview patients and survey healthcare professionals to understand u…
Sponsor: Dorothy House Hospice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
10,000-Patient study aims to unlock best of both worlds for arthritis
Knowledge-focused Recruiting nowThis large observational study will follow 10,000 people with rheumatoid arthritis (RA) who are receiving a combination of Traditional Chinese Medicine (TCM) and standard Western medicine. Researchers will collect health data and biological samples over time to understand which t…
Sponsor: Yuanyuan Zhang • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Researchers launch study to unravel mysteries of rare immune disorder sHLH
Knowledge-focused Recruiting nowThis study aims to understand why some adults develop secondary hemophagocytic lymphohistiocytosis (sHLH), a serious immune condition causing fevers and organ damage. Researchers will follow 300 participants for up to 3 years, collecting blood samples and medical data to identify…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New MRI score could improve CRMO monitoring in kids
Knowledge-focused Recruiting nowThis study looks at whether a new way of scoring whole-body MRI scans can reliably measure bone inflammation in children with CRMO, a rare condition causing repeated bone pain and swelling. Researchers will compare the MRI scores from different doctors and also check if changes i…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists launch hunt for clues in autoimmune skin diseases
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists launch biobank to unlock secrets of arthritis and bone disease
Knowledge-focused Recruiting nowThis study is creating a biobank of blood and tissue samples from 2,000 people with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, or osteoporosis. Researchers will analyze these samples to find biomarkers that predict how well a patient responds to treatment. The …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Blood samples could unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Rare disease CACP syndrome under the microscope: new study aims to unlock its secrets
Knowledge-focused Recruiting nowThis study is gathering information from 15 people with CACP syndrome, a rare genetic condition that causes joint problems and sometimes heart issues. Researchers want to better understand how the disease develops and changes over time. The goal is to improve diagnosis and care f…
Sponsor: Meyer Children's Hospital IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Should you get your COVID and flu shots together? new study aims to find out for immunocompromised patients
Knowledge-focused Recruiting nowThis study is testing whether giving the COVID-19 booster and flu vaccine at the same time is as good as giving them a month apart for people with weakened immune systems. It also compares getting a COVID-19 booster every 3 months versus every 6 months. The trial involves 660 adu…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Could your home be making your lung disease worse?
Knowledge-focused Recruiting nowThis study looks at 100 adults with fibrosing interstitial lung diseases (a type of lung scarring) to see if things like mold, dust, air pollution, and other home factors make the disease progress faster. Researchers will compare patients whose disease is getting worse to those w…
Sponsor: Ville de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Scientists hunt for hidden genes behind mysterious fevers
Knowledge-focused Recruiting nowThis study is looking for new genes and biological markers that cause systemic autoinflammatory diseases (SAIDs), a group of rare conditions that cause repeated fevers and inflammation. Researchers will analyze the DNA and blood of 300 patients to find disease-causing mutations a…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
5,000-Patient study aims to unlock sarcoidosis mysteries
Knowledge-focused Recruiting nowThis study looks at why sarcoidosis affects people differently—some get better, others develop long-term lung damage. Researchers will analyze genes, immune cells, and gut bacteria from 5,000 participants, including healthy volunteers. The goal is to find markers that predict dis…
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New bone scanners could predict fractures better than current methods
Knowledge-focused Recruiting nowThis study uses two special scanners (HR-pQCT and pQCT) to take detailed pictures of bone and muscle in 1,000 people with conditions that raise the risk of bone loss, like osteoporosis, arthritis, or kidney disease. The goal is to see if these scanners can spot tiny changes in bo…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Scientists probe immune cells to unlock secrets of sarcoidosis and TB
Knowledge-focused Recruiting nowThis study looks at how certain immune cells (monocytes and macrophages) behave in sarcoidosis and tuberculosis. Researchers will compare blood and tissue samples from 100 adults to find patterns that explain why these cells stay overactive in sarcoidosis. The goal is to better u…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Smart knee replacement: data platform aims to cut risks
Knowledge-focused Recruiting nowThis pilot study will enroll 600 people getting total knee replacements to test a data platform called Pheno4U. Participants will use a sensor and a smartphone app to track their recovery. The goal is to identify unknown risks or side effects and improve personalized care. The st…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Could your body clock affect rare inflammatory disease?
Knowledge-focused Recruiting nowThis study looks at whether people with CAPS (a rare genetic inflammatory condition) have disrupted circadian rhythms—the body's natural day-night cycle. Researchers will measure melatonin levels and track activity with a watch in 30 participants (patients and healthy household m…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New study uses DNA tests to catch blood cancers before they start
Knowledge-focused Recruiting nowThis study is looking at 2,000 people who have early warning signs of blood cancers or bone marrow failure. Researchers use a special genetic test (next generation sequencing) to find changes in cancer-related genes. The goal is to better understand who is at risk and to catch th…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC